Daiichi Life Insurance Co. Ltd. purchased a new stake in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) in the 2nd quarter, Holdings Channel reports. The institutional investor purchased 5,327 shares of the medical research company’s stock, valued at approximately $1,446,000.
Other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. purchased a new position in shares of Natera during the 2nd quarter valued at about $2,962,770,000. Coatue Management LLC increased its holdings in Natera by 1,446.1% in the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock worth $603,270,000 after acquiring an additional 2,463,008 shares in the last quarter. Wellington Management Group LLP raised its stake in Natera by 94.7% during the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock worth $1,140,026,000 after acquiring an additional 2,420,263 shares during the period. Norges Bank purchased a new position in Natera during the fourth quarter valued at approximately $372,398,000. Finally, JPMorgan Chase & Co. lifted its holdings in Natera by 10.5% during the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after purchasing an additional 1,225,420 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.
Natera Price Performance
Natera stock opened at $332.03 on Monday. Natera, Inc. has a 1 year low of $157.43 and a 1 year high of $333.56. The firm’s 50 day moving average price is $274.24 and its 200-day moving average price is $229.38. The stock has a market cap of $47.86 billion, a P/E ratio of -244.14 and a beta of 1.51.
Analyst Ratings Changes
A number of analysts have recently issued reports on NTRA shares. Leerink Partners set a $330.00 price objective on shares of Natera in a research note on Friday, August 7th. Wall Street Zen cut shares of Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Stephens raised their price target on Natera from $305.00 to $350.00 and gave the company an “overweight” rating in a report on Wednesday, August 12th. Canaccord Genuity Group set a $375.00 price objective on Natera in a research report on Friday, August 7th. Finally, UBS Group set a $260.00 price objective on Natera in a research note on Wednesday, June 24th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $319.38.
View Our Latest Report on NTRA
Insider Buying and Selling at Natera
In related news, Director Herm Rosenman sold 16,530 shares of the business’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $250.00, for a total value of $4,132,500.00. Following the sale, the director directly owned 4,250 shares in the company, valued at approximately $1,062,500. The trade was a 79.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Solomon Moshkevich sold 3,410 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $265.58, for a total value of $905,627.80. Following the transaction, the insider directly owned 129,019 shares of the company’s stock, valued at approximately $34,264,866.02. The trade was a 2.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 181,045 shares of company stock worth $41,330,968. Insiders own 5.05% of the company’s stock.
Natera Profile
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Featured Stories
- Five stocks we like better than Natera
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
